The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Mar 17, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how effective a new imaging technique, which combines two types of PET scans using special tracers (18F-FDG and 18F-FAPI), is in assessing the response of gastric cancer to neoadjuvant therapy. Neoadjuvant therapy involves giving treatment before surgery to shrink tumors and improve the chances of successful surgery. The goal of the trial is to see if this advanced imaging can help doctors better evaluate how well the treatment is working, guide further treatment decisions, and allow patients to move to surgery sooner.

To be eligible for this trial, participants must be at least 18 years old and have been diagnosed with primary gastric adenocarcinoma that has not yet been surgically treated. They should also have undergone imaging before starting neoadjuvant therapy and be willing to undergo additional imaging and surgery afterward. Participants can expect to have their tumor responses closely monitored through these advanced imaging techniques, which may provide more accurate information than traditional methods. This trial is currently recruiting participants, and those interested should discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed primary gastric adenocarcinoma patients (cT2N+non-surgical treatment, cT3NanyMany and above staging)
• • Staging of MRI enhanced examination before neoadjuvant therapy
• • Restaging of preoperative 18F-FAPI and 18F-FDG PET/MRI examination
• • Postoperative resection was performed after neoadjuvant therapy, with postoperative pathology, regression grading, and related immunohistochemistry
• • Patient age ≥ 18 years old
• • The patient voluntarily participates and signs an informed consent form.
• Exclusion Criteria:
• • Severe comorbidities may interfere with treatment or affect disease-specific health-related quality of life
• • Drug requirements that interfere with the research protocol
• • Pregnant or lactating male subjects who are expected to conceive or cause their spouse to conceive during the planned trial period
• • The imaging quality is poor and cannot be used for diagnosis and evaluation.